Alan Tan

And, you know, I mean, of course it was in the cis-plan ineligible population.

Are you guys using it in cis-eligible populations?

Can you see a world where CIS-eligible would show you something dramatically different, the opposite?

I know we're all academic ecologists here and we have to say the right thing, but really, if that was you, if this is your family member, what are you giving them?

I'm putting you guys on the spot.

Brad's willing to at least say that much.

But yeah, I mean, for me, cisplatin's dead.

Let's just be honest.

At least in the perioperative setting and in a frontline metastatic setting, for most people, or like 90% of people, right, I think it's pretty easy to make somebody cisplatin ineligible.

You know, the criteria is not too much of a fine line, creatinine clearance, etc., so...

Yeah.

And for me, like, you know, I don't see too many cirrhotic patients, maybe mild hepatic dysfunction.

I might dose reduce for those patients.

But I maybe worry more about uncontrolled diabetics because, well, you have seen people die of DKA, right?

So those are the ones maybe are not going to be as eligible, I would say.

And, you know, we even talk about variant histology.

I don't think we should be giving Evie Pembroke for squamous, right?

What do you guys agree?

I think is where you really... Although anecdotally, I'm very bullish on plasma cytoid and EV Pembro.

Had some really unprecedented responses.